sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.
|
cisplatin
|
5-fluorouracil
|
NONE
|
Dolasetron_ddi.xml
|
DDI-DrugBank.d42.s7
|
DDI-DrugBank.d42.s7.p9
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
anticholinergic
|
phenothiazines
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p3
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
|
epinephrine
|
norepinephrine
|
NONE
|
Bupivacaine_ddi.xml
|
DDI-DrugBank.d153.s0
|
DDI-DrugBank.d153.s0.p4
|
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
|
Imidazoles
|
miconazole
|
NONE
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s8
|
DDI-DrugBank.d318.s8.p1
|
A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.
|
diclofenac
|
insulin
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s13
|
DDI-DrugBank.d249.s13.p0
|
Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.
|
heparin sodium
|
dicumarol
|
ADVISE
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s1
|
DDI-DrugBank.d488.s1.p0
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
ergotamine
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p89
|
Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.
|
Barbiturates
|
fludrocortisone acetate
|
MECHANISM
|
Fludrocortisone_ddi.xml
|
DDI-DrugBank.d526.s17
|
DDI-DrugBank.d526.s17.p2
|
However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechlorethamine.
|
allopurinol
|
cyclophosphamide
|
NONE
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s19
|
DDI-DrugBank.d413.s19.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
felbamate
|
topiramate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p649
|
Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.
|
pentamidine
|
HIVID
|
EFFECT
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s16
|
DDI-DrugBank.d263.s16.p0
|
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin.
|
carboxymethylcellulose-cysteine
|
NaFlu
|
NONE
|
11154900.xml
|
DDI-MedLine.d76.s1
|
DDI-MedLine.d76.s1.p15
|
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.
|
warfarin
|
piroxicam
|
NONE
|
Fondaparinux sodium_ddi.xml
|
DDI-DrugBank.d15.s1
|
DDI-DrugBank.d15.s1.p6
|
Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;
|
hormonal contraceptives
|
cyclosporine
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s19
|
DDI-DrugBank.d485.s19.p2
|
Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
|
antacids
|
vitamin D
|
ADVISE
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s15
|
DDI-DrugBank.d98.s15.p5
|
When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.
|
duloxetine
|
desipramine
|
MECHANISM
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s8
|
DDI-DrugBank.d548.s8.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
trimethoprim
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p51
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
alcohol
|
miconazole
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p82
|
Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.
|
Adrenergic blockers
|
amphetamines
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s3
|
DDI-DrugBank.d236.s3.p2
|
Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
|
ritonavir
|
combination hormonal contraceptives
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s32
|
DDI-DrugBank.d485.s32.p14
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
cimetidine
|
quinupristin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p93
|
In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
|
amiloride
|
dofetilide
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s22
|
DDI-DrugBank.d558.s22.p5
|
Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.
|
anticholinesterase agents
|
corticosteroids
|
EFFECT
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s4
|
DDI-DrugBank.d314.s4.p2
|
Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.
|
fentanyl
|
beta blocker
|
EFFECT
|
Isradipine_ddi.xml
|
DDI-DrugBank.d81.s14
|
DDI-DrugBank.d81.s14.p3
|
A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.
|
lopinavir
|
SUSTIVA
|
ADVISE
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s42
|
DDI-DrugBank.d531.s42.p1
|
Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
|
Lithium
|
Valdecoxib
|
NONE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s20
|
DDI-DrugBank.d328.s20.p0
|
Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).
|
quinidine
|
nifedipine
|
MECHANISM
|
Nifedipine_ddi.xml
|
DDI-DrugBank.d373.s8
|
DDI-DrugBank.d373.s8.p3
|
As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.
|
adenosine
|
carbamazepine
|
EFFECT
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s9
|
DDI-DrugBank.d226.s9.p0
|
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole.
|
nitrosourea
|
misonidazole
|
NONE
|
3966974.xml
|
DDI-MedLine.d85.s1
|
DDI-MedLine.d85.s1.p2
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
serotoninergic agents
|
sertraline
|
NONE
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p24
|
Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
|
Digitalis
|
digitalis
|
NONE
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s7
|
DDI-DrugBank.d404.s7.p1
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
bacitracin
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p3
|
MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
|
furazolidone
|
amphetamine
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s10
|
DDI-DrugBank.d236.s10.p5
|
Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.
|
angiotensin converting enzyme inhibitors
|
azathioprine
|
EFFECT
|
Azathioprine_ddi.xml
|
DDI-DrugBank.d233.s3
|
DDI-DrugBank.d233.s3.p2
|
Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.
|
benzothiadiazines
|
ethacrynic acid
|
NONE
|
Fludrocortisone_ddi.xml
|
DDI-DrugBank.d526.s1
|
DDI-DrugBank.d526.s1.p7
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
sulfonamides
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p18
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
cetirizine
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p2
|
Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
|
rifampin
|
bexarotene
|
MECHANISM
|
Bexarotene_ddi.xml
|
DDI-DrugBank.d467.s3
|
DDI-DrugBank.d467.s3.p2
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
Butalbital
|
narcotic analgesic
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p2
|
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
|
aluminum hydroxide
|
fosinopril
|
MECHANISM
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s9
|
DDI-DrugBank.d176.s9.p19
|
Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
|
Tricyclic antidepressants
|
combination hormonal contraceptives
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s41
|
DDI-DrugBank.d485.s41.p3
|
Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.
|
Sodium cephalothin
|
Coly-Mycin M
|
EFFECT
|
Colistimethate_ddi.xml
|
DDI-DrugBank.d250.s3
|
DDI-DrugBank.d250.s3.p0
|
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
|
iron
|
cobalt
|
MECHANISM
|
7599505.xml
|
DDI-MedLine.d34.s7
|
DDI-MedLine.d34.s7.p0
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
monoamine oxidase inhibitors
|
paroxetine
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p5
|
Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
|
quinidine
|
selective serotonin reuptake inhibitors
|
NONE
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s16
|
DDI-DrugBank.d223.s16.p0
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
vitamin K
|
ethchlorvynol
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p186
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
caffeine
|
tranquilizers
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p20
|
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
|
fluoxetine
|
alprazolam
|
MECHANISM
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s5
|
DDI-DrugBank.d131.s5.p7
|
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
|
clonazepam
|
propantheline
|
MECHANISM
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s3
|
DDI-DrugBank.d333.s3.p14
|
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of eplerenone with an NSAID has not been conducted.
|
eplerenone
|
NSAID
|
NONE
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s10
|
DDI-DrugBank.d20.s10.p5
|
Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
|
TRISENOX
|
amphotericin B
|
ADVISE
|
Arsenic trioxide_ddi.xml
|
DDI-DrugBank.d470.s1
|
DDI-DrugBank.d470.s1.p3
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
Sparine
|
trifluoperazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p249
|
Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.
|
Beta-adrenergic blocking drugs
|
captopril
|
EFFECT
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s12
|
DDI-DrugBank.d175.s12.p0
|
Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.
|
ARAVA
|
rifampin
|
ADVISE
|
Leflunomide_ddi.xml
|
DDI-DrugBank.d41.s15
|
DDI-DrugBank.d41.s15.p2
|
In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
|
warfarin
|
phenytoin
|
NONE
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s11
|
DDI-DrugBank.d460.s11.p51
|
Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
|
ketoconazole
|
cisapride
|
EFFECT
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s8
|
DDI-DrugBank.d458.s8.p0
|
THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
|
NON-NARCOTIC ANALGESICS
|
BARBITURATES
|
NONE
|
Hydroxyzine_ddi.xml
|
DDI-DrugBank.d308.s0
|
DDI-DrugBank.d308.s0.p9
|
Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
|
diuretics
|
adrenergic agonists
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s3
|
DDI-DrugBank.d284.s3.p14
|
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
|
clozapine
|
carbamazepine
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s30
|
DDI-DrugBank.d480.s30.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
tramadol
|
ziprasidone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p1023
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
quinolone
|
zinc
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p8
|
Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
|
voriconazole
|
itraconazole
|
NONE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s10
|
DDI-DrugBank.d364.s10.p14
|
There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.
|
tricyclic antidepressants
|
fluoxetine
|
MECHANISM
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s28
|
DDI-DrugBank.d386.s28.p0
|
Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
|
capecitabine
|
phenprocoumon
|
EFFECT
|
Capecitabine_ddi.xml
|
DDI-DrugBank.d88.s3
|
DDI-DrugBank.d88.s3.p6
|
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
|
ascorbic acid
|
amphetamines
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s0
|
DDI-DrugBank.d236.s0.p20
|
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
|
cephalosporins
|
diuretics
|
EFFECT
|
Ceftazidime_ddi.xml
|
DDI-DrugBank.d122.s0
|
DDI-DrugBank.d122.s0.p1
|
There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.
|
quinolones
|
theophylline
|
EFFECT
|
Nalidixic Acid_ddi.xml
|
DDI-DrugBank.d427.s1
|
DDI-DrugBank.d427.s1.p2
|
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
|
Tagamet
|
metronidazole
|
MECHANISM
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s0
|
DDI-DrugBank.d171.s0.p9
|
Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.
|
linezolid
|
adrenergic
|
INT
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s1
|
DDI-DrugBank.d441.s1.p0
|
The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.
|
lithium
|
TORADOL
|
NONE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s12
|
DDI-DrugBank.d3.s12.p4
|
In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.
|
piperacillin
|
vecuronium
|
EFFECT
|
Piperacillin_ddi.xml
|
DDI-DrugBank.d462.s3
|
DDI-DrugBank.d462.s3.p0
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
Levo-Dromoran
|
central nervous system depressants
|
EFFECT
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p0
|
Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
|
ketoconazole
|
cimetidine
|
NONE
|
Felodipine_ddi.xml
|
DDI-DrugBank.d316.s1
|
DDI-DrugBank.d316.s1.p2
|
In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 m m M i.e., 350 mg/L) was 17-28%.
|
coumarin
|
fondaparinux
|
MECHANISM
|
Fondaparinux sodium_ddi.xml
|
DDI-DrugBank.d15.s4
|
DDI-DrugBank.d15.s4.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Gris-PEG
|
theophylline
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p552
|
Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
thyroid products
|
antidiabetic drugs
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s15
|
DDI-DrugBank.d460.s15.p11
|
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
|
ketoconazole
|
budesonide
|
ADVISE
|
Budesonide_ddi.xml
|
DDI-DrugBank.d144.s1
|
DDI-DrugBank.d144.s1.p5
|
Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.
|
amphotericin B
|
nelfinavir
|
NONE
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s3
|
DDI-DrugBank.d350.s3.p10
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
asparaginase
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p2
|
When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.
|
lansoprazole
|
theophylline
|
MECHANISM
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s3
|
DDI-DrugBank.d431.s3.p0
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
amiodarone
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p69
|
Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
|
CNS depressants
|
hydrocodone
|
EFFECT
|
Hydrocodone_ddi.xml
|
DDI-DrugBank.d396.s0
|
DDI-DrugBank.d396.s0.p16
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
carbamazepine
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p1
|
No drug interaction studies have been conducted for COLAZAL, however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.
|
antibiotics
|
mesalamine
|
NONE
|
Balsalazide_ddi.xml
|
DDI-DrugBank.d486.s0
|
DDI-DrugBank.d486.s0.p2
|
Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
|
decongestants
|
tricyclic antidepressants
|
ADVISE
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s2
|
DDI-DrugBank.d77.s2.p4
|
ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
|
NSAIDs
|
ACE-inhibitors
|
EFFECT
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s8
|
DDI-DrugBank.d328.s8.p2
|
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
|
MAOI
|
flupenthixol
|
EFFECT
|
Flupenthixol_ddi.xml
|
DDI-DrugBank.d13.s0
|
DDI-DrugBank.d13.s0.p30
|
The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
|
quinidine
|
antihistamines
|
NONE
|
Dicyclomine_ddi.xml
|
DDI-DrugBank.d543.s0
|
DDI-DrugBank.d543.s0.p18
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
ciprofloxacin
|
magnesium
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p10
|
In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium 5.5 mEq/L) from 17% on enalapril alone to 38%.
|
INSPRA
|
enalapril
|
EFFECT
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s7
|
DDI-DrugBank.d20.s7.p1
|
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats.
|
cobalt
|
Fe
|
NONE
|
7599505.xml
|
DDI-MedLine.d34.s1
|
DDI-MedLine.d34.s1.p2
|
Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.
|
MTX
|
corticosteroids
|
NONE
|
Abatacept_ddi.xml
|
DDI-DrugBank.d297.s1
|
DDI-DrugBank.d297.s1.p1
|
Lithium: Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.
|
Nonsteroidal anti-inflammatory agents
|
lithium
|
MECHANISM
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s24
|
DDI-DrugBank.d499.s24.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Invirase
|
Kadian
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p859
|
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, sedatives, tranquilizers).
|
antiemetics
|
tranquilizers
|
NONE
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s1
|
DDI-DrugBank.d114.s1.p13
|
Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
|
Estrogens
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s17
|
DDI-DrugBank.d314.s17.p5
|
Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.
|
itraconazole
|
VIDEX
|
ADVISE
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s5
|
DDI-DrugBank.d43.s5.p2
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
fentanyl
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p62
|
Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
|
Aprepitant
|
nelfinavir
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s31
|
DDI-DrugBank.d382.s31.p6
|
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
|
ALFENTA
|
anesthetics
|
EFFECT
|
Alfentanil_ddi.xml
|
DDI-DrugBank.d8.s0
|
DDI-DrugBank.d8.s0.p4
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.